Mega Lifesciences Public Company Limited (SET: MEGA) has announced its 1Q22 consolidated financial statement through the Stock Exchange of Thailand as follows;
| Quarter | 1Q22 | 1Q21 |
| Net Profit (Loss) Million Baht |
613.99 | 333.55 |
| Earning Per Share (Baht) |
0.7000 | 0.3800 |
| % Change | 84.08 | |
MEGA reported a net profit of THB 613 million in 1Q22, increased 84% from a net profit of THB 333 million in 1Q21. The increase was mainly a result of growth in Mega We Care revenue and better gross margins.
Overall operating revenue in 1Q22 was THB 3,820mn, higher by 16.8% YoY. The revenue growth in 1Q22 was driven by the Mega We Care business. Mega We Care revenue was THB 1,954mn in 1Q22 (up by 32.6% YoY).
Overall gross margin in 1Q22 improved to 44.8% compared to 38.4% in 1Q21. Improvement in 1Q22 gross margin was mainly a result of growth in Mega We Care revenue causing favourable revenue mix and better segmental gross margins.
